300244 迪安诊断
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入9,258,111-10.05%13,408,32020,282,46913,082,61310,649,162
减:营业总成本8,491,254-5.42%12,243,28216,603,82111,084,4098,862,648
    其中:营业成本6,661,093-3.67%9,213,38312,745,8118,076,9496,578,706
               财务费用151,791-10.43%220,608298,236217,479195,875
               资产减值损失767-199.27%(16,738)(624,025)(272,189)(475,247)
公允价值变动收益(15,805)-162.53%(727)(56,236)83,354(2,586)
投资收益9,1841,353.03%(17,596)48,78755,33873,148
    其中:对联营企业和合营企业的投资收益12,637-10,913.30%(6,722)26,76339,78520,783
营业利润435,847-57.78%842,1832,822,6091,837,9351,320,311
利润总额424,172-58.47%798,3262,543,5621,790,9971,317,395
减:所得税费用121,488-47.18%216,735681,092307,396247,461
净利润302,684-61.75%581,5911,862,4701,483,6011,069,934
减:非控股权益171,827-34.05%274,130428,279320,717267,002
股东净利润130,857-75.35%307,4611,434,1911,162,884802,933

市场价值指针
每股收益 (元) *0.212-74.99%0.4922.3021.8741.294
每股派息 (元) *0.650--0.0600.2000.1350.130
每股净资产 (元) *11.292-9.78%12.06911.8819.4167.572
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容